Systematic Review

Published on 02 Aug 2023

Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Yanhong Pan
Panting Wan
Li Zhang
Cuirong Wang
Yijun Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1185987

1,893 views
3 citations

Original Research

Published on 28 Jul 2023

Research trends and hotspots on the links between caveolin and cancer: bibliometric and visual analysis from 2003 to 2022

in Pharmacology of Anti-Cancer Drugs

Yaqian Tan
Qi Song

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1237456

2,475 views
2 citations

Review

Published on 28 Jul 2023

Darovasertib, a novel treatment for metastatic uveal melanoma

in Pharmacology of Anti-Cancer Drugs

Lei Cao
Shuzhen Chen
Rainie Sun
Charles R. Ashby
Liuya Wei
Zoufang Huang
Zhe-Sheng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1232787

11,829 views
12 citations

Systematic Review

Published on 27 Jul 2023

Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer

in Pharmacology of Anti-Cancer Drugs

Zhen-Chu Tang
Qiang Qu
Xin-Qi Teng
Hai-Hui Zhuang
Wei-Xin Xu
Jian Qu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1192855

2,361 views

Review

Published on 26 Jul 2023

Targeting copper metabolism: a promising strategy for cancer treatment

in Pharmacology of Anti-Cancer Drugs

Ruimin Kong
Guojuan Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1203447

5,160 views
18 citations

Review

Published on 26 Jul 2023

Anticancer therapeutic effect of ginsenosides through mediating reactive oxygen species

in Pharmacology of Anti-Cancer Drugs

Xiaonan Li
Donghui Cao
Siming Sun
Yuehui Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1215020

2,140 views
4 citations

Correction

Published on 26 Jul 2023

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

in Pharmacology of Anti-Cancer Drugs

Ningning Yan
Siyuan Huang
Linlin Li
Qianqian Guo
Di Geng
Huixian Zhang
Sanxing Guo
Xingya Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1256801

929 views

Original Research

Published on 25 Jul 2023

A novel classifier combining G protein-coupled receptors and the tumor microenvironment is associated with survival status in glioblastoma

in Pharmacology of Anti-Cancer Drugs

Chunyu Guo
Cong Yu
Weizhen Gao
Dabin Ren
Yisong Zhang
Ping Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1093263

1,707 views

Original Research

Published on 24 Jul 2023

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

in Pharmacology of Anti-Cancer Drugs

Ying Zhang
Li Ran
Yongchao Liang
Yanqiu Zhang
Zhuoling An

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1194545

2,816 views
8 citations

Original Research

Published on 19 Jul 2023

Development of an MCL-1-related prognostic signature and inhibitors screening for glioblastoma

in Pharmacology of Anti-Cancer Drugs

Ao Zhang
Zhen Guo
Jia-xin Ren
Hongyu Chen
Wenzhuo Yang
Yang Zhou
Lin Pan
Zhuopeng Chen
Fei Ren
Youqi Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1162540

2,538 views
3 citations

Original Research

Published on 19 Jul 2023

Integrative analysis illustrates the role of PCDH7 in lung cancer development, cisplatin resistance, and immunotherapy resistance: an underlying target

in Pharmacology of Anti-Cancer Drugs

Huakang Li
Haoran Xu
Hong Guo
Kangming Du
Diang Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1217213

2,695 views
2 citations

Original Research

Published on 19 Jul 2023

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

in Pharmacology of Anti-Cancer Drugs

Alberto Blanco Sánchez
Rodrigo Gil Manso
Gonzalo Carreño-Tarragona
Diana Paredes Ruiz
Jesús González Olmedo
Joaquín Martínez-López
Carmen Díaz Pedroche
Rosa Ayala

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1206893

1,581 views

Original Research

Published on 19 Jul 2023

Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPARγ and CaMKII signaling pathway

in Pharmacology of Anti-Cancer Drugs

Nan-Nan Chen
Xin-Di Ma
Zhuang Miao
Xiang-Mei Zhang
Bo-Ye Han
Ahmed Ali Almaamari
Jia-Min Huang
Xue-Yan Chen
Yun-Jiang Liu
Su-Wen Su

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1150861

5,520 views
15 citations

Original Research

Published on 18 Jul 2023

To explore the effect of kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking

in Pharmacology of Anti-Cancer Drugs

Junli Zhang
Xiangqi Liu
Guoying Zhang
Junling Wu
Zhongfang Liu
Chuanguo Liu
Hui Wang
Shuxin Miao
Lei Deng
Kuan Cao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1148171

4,002 views
2 citations

Original Research

Published on 17 Jul 2023

Cuproptosis-related lncRNAs potentially predict prognosis and therapy sensitivity of breast cancer

in Pharmacology of Anti-Cancer Drugs

Xiwen Wu
Ying Zhang
Gehao Liang
Huizhen Ye

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1199883

3,331 views
5 citations

Case Report

Published on 17 Jul 2023

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors

in Pharmacology of Anti-Cancer Drugs

Jianxin Chen
Junhui Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1190447

1,434 views
1 citation

Navigation group

Articles

Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis

Research trends and hotspots on the links between caveolin and cancer: bibliometric and visual analysis from 2003 to 2022

Darovasertib, a novel treatment for metastatic uveal melanoma

Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer

Targeting copper metabolism: a promising strategy for cancer treatment

Anticancer therapeutic effect of ginsenosides through mediating reactive oxygen species

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

A novel classifier combining G protein-coupled receptors and the tumor microenvironment is associated with survival status in glioblastoma

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

Development of an MCL-1-related prognostic signature and inhibitors screening for glioblastoma

Integrative analysis illustrates the role of PCDH7 in lung cancer development, cisplatin resistance, and immunotherapy resistance: an underlying target

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPARγ and CaMKII signaling pathway

To explore the effect of kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking

Cuproptosis-related lncRNAs potentially predict prognosis and therapy sensitivity of breast cancer

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors